Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Technology Offers More Potent Delivery of Cannabinoids
Technology that improves bioavailability of orally ingested cannabinoids Safer approach that mitigates risks from carcinogens Generates revenue by out-licensing its technology internationally Announcement of a new government initiative to reduce the level of nicotine in cigarettes to nonaddictive levels is good news for Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP). Less addictive cigarettes mean less dependence on smoking as a delivery system, not only for nicotine but other substances like cannabinoids, which is why the folks at Lexaria are cheering the Food and Drug Administration (FDA) on. This innovative bioscience company has developed technology that offers a safer and more efficient…